Xun Zhao

Title: Xun Zhao: Innovator in Pharmaceutical Development

Introduction

Xun Zhao is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on drug formulations. His research focuses on enhancing drug efficacy and reducing adverse effects.

Latest Patents

Xun Zhao holds a patent for a "Memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application." This invention provides a cocrystal salt of memantine paroxetine sulfate hydrate. The mechanism of action involves being a 5-HT inhibitor and NMDA receptor antagonist, making it a multi-target drug. Preliminary pharmacokinetic experiments have shown that the cocrystal salt significantly improves drug absorption, blood drug concentration, bioavailability, and curative effect. This advancement offers a material basis for reducing dosage and adverse drug reactions.

Career Highlights

Xun Zhao is currently associated with Hefei Keda Bio-technology Co. Ltd. His work has been pivotal in developing new pharmaceutical compositions that can be combined with other drugs to achieve unexpected clinical efficacy. His innovative approach has the potential to transform treatment protocols in various medical fields.

Collaborations

Xun Zhao has collaborated with notable colleagues, including Ke Wang and Qianliu Cheng. Their combined expertise has contributed to the successful development of innovative pharmaceutical solutions.

Conclusion

Xun Zhao's contributions to pharmaceutical innovation highlight the importance of multi-target drugs in modern medicine. His work not only enhances drug efficacy but also aims to minimize adverse effects, paving the way for improved patient outcomes.